Premium
miR‐146b overexpression ameliorates lipopolysaccharide‐induced acute lung injury in vivo and in vitro
Author(s) -
He Ruoxi,
Li Ying,
Zhou Li,
Su Xiaoli,
Li Yuanyuan,
Pan Pinhua,
Hu Chengping
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.26846
Subject(s) - lipopolysaccharide , in vivo , in vitro , lung , microbiology and biotechnology , chemistry , medicine , immunology , biology , biochemistry
Acute respiratory distress syndrome (ARDS) is a type of acute lung injury (ALI), which causes high morbidity and mortality. So far, effective clinical treatment of ARDS is still limited. Recently, miR‐146b has been reported to play a key role in inflammation. In the present study, we evaluated the functional role of miR‐146b in ARDS using the murine model of lipopolysaccharide (LPS)‐induced ALI. The miR‐146b expression could be induced by LPS stimulation, and miR‐146b overexpression was required in the maintenance of body weight and survival of ALI mice; after miR‐146b overexpression, LPS‐induced lung injury, pulmonary inflammation, total cell and neutrophil counts, proinflammatory cytokines, and chemokines in bronchial alveolar lavage (BAL) fluid were significantly reduced. The promotive effect of LPS on lung permeability through increasing total protein, albumin and IgM in BAL fluid could be partially reversed by miR‐146b overexpression. Moreover, in murine alveolar macrophages, miR‐146b overexpression reduced LPS‐induced TNF‐α and interleukin (IL)‐1β releasing. Taken together, we demonstrated that miR‐146b overexpression could effectively improve the LPS‐induced ALI; miR‐146b is a promising target in ARDS treatment.